Order results by:
| Issue | Title | |
| Vol 4, No 2 (2012) | Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease | Abstract similar documents |
| S N Illarioshkin | ||
| "... Dopaminergic stimulation with levodopa, a biological precursor of dopamine precursor, and dopamine ..." | ||
| Vol 6, No 3 (2014) | Current therapy for Parkinson's disease | Abstract similar documents |
| A. V. Obukhova | ||
| "... in the nigrostriatal system. Levodopa preparations and dopamine receptor agonists (DRAs) that are prescribed ..." | ||
| Vol 16, No 2 (2024) | Efficacy of antiparkinsonian therapy in tremor correction according to tremorography | Abstract similar documents |
| V. A. Bogacheva, D. V. Zakharov, V. A. Mikhailov | ||
| "... of four drugs in monotherapy: dopamine receptor agonists (ADR; pramipexole), levodopa (Tidomet forte ..." | ||
| Vol 3, No 4 (2011) | Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole | Abstract similar documents |
| M. R. Nodel | ||
| "... pramipexole (Mirapex). Patients and methods. Sixty patients with PD (disease duration 6.02±3.47 years; stage ..." | ||
| Vol 3, No 1 (2011) | Sleep disorders in Parkinson's disease | Abstract similar documents |
| M. R. Nodel | ||
| "... 63.2±9.9 years; mean PD duration 6.5±4.2 years) were followed up. Forty patients received pramipexole ..." | ||
| Vol 4, No 1 (2012) | Sustained-release pramipexole in the treatment of Parkinson’s disease | Abstract similar documents |
| Natalia Vladimirovna Fedorova | ||
| "... for dopaminergic deficiency in Parkinson’s disease (PD). Since 1996, pramipexole has been used to treat early ..." | ||
| Vol 6, No 1 (2014) | Apathy in Parkinson's disease patients | Abstract similar documents |
| M. R. Nodel | ||
| "... to the Hoehn and Yahr scale, 2.5) received pramipexole (1.5–3.0 mg/day) to correct motor disorders ..." | ||
| Vol 4, No 3 (2012) | Clinical experience with requip modutab | Abstract similar documents |
| Denis Valeryevich Zakharov, V A Mikhailov | ||
| "... The efficacy of dopamine receptor agonists (DRAs) is determined by a number of advantages. DRAs ..." | ||
| Vol 5, No 3 (2013) | The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease | Abstract similar documents |
| Marina Romanovna Nodel | ||
| "... Rotigotine is a new, non-ergot dopamine receptor agonist (DRA) formulated as a transdermal drug ..." | ||
| Vol 13, No 3 (2021) | Profile and frequency of antiparkinsonian drugs adverse reactions: a systematic review and meta-analysis | Abstract similar documents |
| A. A. Tappakhov, T. E. Popova, A. I. Vasilev, T. G. Govorova, Yu. I. Khabarova, K. A. Timofeeva, N. A. Schnaider | ||
| "... (OR) and 95% confidence interval (95% CI) calculation. Results and discussion. Levodopa/benserazide (LB) had ..." | ||
| Vol 7, No 3 (2015) | Experience in using levodopa-benserazide | Abstract similar documents |
| Elena Anatolyevna Katunina, Yu. N. Bezdolnyi, E. A. Malykhina, N. V. Titova | ||
| "... Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper ..." | ||
| Vol 15, No 6 (2023) | Effect of dopaminergic therapy on lacrimation in Parkinson's disease | Abstract similar documents |
| A. A. Pilipovich, O. V. Vorob'eva, S. A. Makarov, A. V. Kuchuk | ||
| "... to Hoehn and Yahr (H&Y) receiving therapy with levodopa (n=17), amantadines (n=13) and dopamine receptor ..." | ||
| Vol 5, No 1 (2013) | Practical aspects of the use of extended-release ropinirole (requip modutab) in the treatment of Parkinson’s disease | Abstract similar documents |
| Oleg Semenovich Levin, V K Datiyeva | ||
| "... receptor agonist (DRAs), which has been widely used to treat Parkinson’s disease (PD) in foreign countries ..." | ||
| Vol 16, No 3 (2024) | Treatment of the early stages of Parkinson's disease. Differences in approaches to the choice of therapy in different countries | Abstract similar documents |
| E. V. Bril, N. V. Fedorova, T. K. Kulua, O. S. Zimnyakova | ||
| "... country, dopamine receptor agonists (DRAs) are currently one of the most commonly prescribed groups ..." | ||
| Vol 15, No 3 (2023) | Parkinson’s disease. Focus on early stages | Abstract similar documents |
| E. A. Katunina, Z. A. Zalyalova, D. V. Pokhabov, M. Z. Ivanova, A. M. Semenova | ||
| "... of age are recommended to start therapy with levodopa; younger patients – with dopamine receptor agonists ..." | ||
| Vol 12, No 1 (2020) | Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease | Abstract similar documents |
| A. A. Tappakhov, T. E. Popova, T. G. Govorova, N. A. Shnaider, M. R. Sapronova | ||
| "... Levodopa remains the gold standard of treating Parkinson's disease (PD). However, the inevitable ..." | ||
| Vol 17, No 3 (2025) | Parkinson's disease and migraine | Abstract similar documents |
| Z. A. Zalyalova, E. A. Katunina, D. V. Pokhabov | ||
| Vol 15, No 3 (2023) | Vitamin B12 deficiency and Parkinson’s disease | Abstract similar documents |
| Z. A. Zalyalova, E. V. Ekusheva | ||
| "... with levodopa (especially its intraduodenal administration), as well as clinical manifestations ..." | ||
| Vol 14, No 6 (2022) | A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study | Abstract similar documents |
| Z. A. Zalyalova, S. E. Munasipova, D. M. Khasanova, G. R. Ilyina, Z. G. Khayatova, N. I. Bagdanova | ||
| "... %), the appearance of "exhaustion" of the effect of a single dose of levodopa (13%), the appearance or increased ..." | ||
| Vol 5, No 1 (2013) | Dopamine dysregulation syndrome in Parkinson’s disease | Abstract similar documents |
| A V Nikitina, Natalia Vladimirovna Fedorova | ||
| "... , the quality-of-life indicators ranged from 19.8 to 90% (54+20.1%). The equivalent dose of levodopa is 1323 ..." | ||
| Vol 13, No 2 (2021) | Drug-induced hypersomnia | Abstract PDF (Eng) similar documents |
| T. M. Ostroumova, O. D. Ostroumova, A. V. Filippova, T. F. Guseva | ||
| "... . Most often, the development of DIH is associated with the use of levodopa-carbidopa, antipsychotics ..." | ||
| Vol 7, No 4 (2015) | Some aspects of treatment for cognitive impairments. Cyticolin: pharmacological characteristics, possible benefits, aspects of use | Abstract similar documents |
| N. V. Trofimova, I. S. Preobrazhenskaya | ||
| "... and to delay of loss of the therapeutic effects of levodopa preparations. Cyticolin has been noted to have ..." | ||
| Vol 10, No 4 (2018) | Nighttime sleep disorders in patients with daytime sleepiness in Parkinson s disease | Abstract similar documents |
| M. R. Nodel, K. V. Shevtsova, G. V. Kovrov, N. N. Yakhno | ||
| "... with levodopa at a mean daily dose of 667.8 mg; 98 of them had the drug in combination with dopamine receptor ..." | ||
| Vol 9, No 3 (2017) | Screening for non-motor symptoms in Parkinson's disease using the NMSQuest scale | Abstract similar documents |
| A. A. Tappakhov, T. E. Popova, T. Ya. Nikolaeva, N. A. Schnaider, M. M. Petrova | ||
| "... with reference to levodopa). Conclusion. The use of questionnaires in patients with PD allows the timely ..." | ||
| 1 - 24 of 24 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
